Alan Burnett, Jamie Cavenagh, Nigel Russell, Robert Hills, Jonathan Kell, Gail Jones, Ove Juul Nielsen, Asim Khwaja, Ian Thomas, Richard Clark, on behalf of the UK NCRI AML Study Group. Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m2 with 6 mg/m2 in the NCRI AML17 Trial. Haematologica 2016;101(6):724-731; https://doi.org/10.3324/haematol.2016.141937.